国际口腔医学杂志 ›› 2022, Vol. 49 ›› Issue (5): 614-620.doi: 10.7518/gjkq.2022064

• 综述 • 上一篇    

免疫检查点抑制剂联合放射治疗在头颈部鳞状细胞癌治疗中的研究进展

李洪芳(),陈中(),张素欣   

  1. 河北医科大学第四医院口腔科 石家庄 050011
  • 收稿日期:2022-01-05 修回日期:2022-05-02 出版日期:2022-09-01 发布日期:2022-09-16
  • 通讯作者: 陈中
  • 作者简介:李洪芳,医师,硕士,Email:1048714296@qq.com
  • 基金资助:
    河北省卫生健康委员会重点科技研究计划(20190695)

Research progress on immune checkpoint inhibitor combined with radiotherapy in head and neck squamous cell carcinoma

Li Hongfang(),Chen Zhong(),Zhang Suxin.   

  1. Dept. of Stomatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
  • Received:2022-01-05 Revised:2022-05-02 Online:2022-09-01 Published:2022-09-16
  • Contact: Zhong Chen
  • Supported by:
    Key Science and Technology Research Program of Hebei Provincial Health Commission(20190695)

摘要:

头颈部鳞状细胞癌(HNSCC)确诊时,多数患者已是局部晚期,传统治疗方法有限,复发率超过50%。以免疫检查点抑制剂(ICI)为主的免疫治疗可以通过激活或增强机体的抗肿瘤免疫功能,杀伤肿瘤细胞或抑制肿瘤发展,为HNSCC患者的治疗带来了新选择,但单独使用ICI药物治疗的效果有限,仅部分患者可以受益。放射治疗是HNSCC的传统治疗方式之一,对免疫功能有重要的调节作用。放射治疗通过直接杀伤肿瘤细胞和促进肿瘤抗原呈递,引发免疫介导的抗肿瘤反应。ICI与放射治疗存在协同抗肿瘤效应,两者结合能够提高抗肿瘤免疫效应。本文就ICI的作用机制及临床进展,以及二者联合在HNSCC治疗中的理论基础及研究现状进行综述,以期更好地指导临床应用。

关键词: 头颈部鳞状细胞癌, 免疫检查点抑制剂, 放射治疗, 联合治疗

Abstract:

Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor. Most patients with HNSCC are in the advanced stage when they are diagnosed. Traditional treatment methods for HNSCC are limited, and the recurrence rate is more than 50%. The development of immunotherapy based on immune checkpoint inhibitors (ICIs) has brought a new option for HNSCC patients. ICIs can kill tumor cells or inhibit the development of tumors by activating or enhancing the antitumor immune function of the body. However, the effectiveness of ICI drug therapy alone is very limited, and only some patients can benefit. Radiotherapy (RT) is one of the traditional treatments for HNSCC. RT can induces immune-mediated antitumor responses by directly killing tumor cells and promoting tumor antigen presentation. ICI has synergistic antitumor effect with radiotherapy, and the combination of ICI and radiotherapy can improve the antitumor immune effect. ICI has synergistic antitumor effect with radiotherapy, and the combination of ICI and radiotherapy can improve the antitumor immune effect. This review summarizes the mechanisms of action and clinical progress of ICI, and the related progress of ICIs combined with RT in HNSCC.

Key words: head and neck squamous cell carcinoma, immune checkpoint inhibitor, radiotherapy, combination the-rapy

中图分类号: 

  • R 782
1 Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2 Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment[J]. Mayo Clin Proc, 2016, 91(3): 386-396.
3 Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer[J]. Lancet, 2008, 371(9625):1695-1709.
4 Morisada M, Chamberlin M, Allen C. Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer[J]. Head Neck, 2018, 40(6): 1321-1334.
5 Sharma P, Allison JP. The future of immune checkpoint therapy[J]. Science, 2015, 348(6230): 56-61.
6 Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition[J]. Am J Clin Oncol, 2016, 39(1): 98-106.
7 Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy[J]. Ann Oncol, 2018, 29(1): 71-83.
8 崔佳宁, 王俊杰. 免疫治疗联合放疗治疗晚期非小细胞肺癌的进展[J]. 现代肿瘤医学, 2018, 26(15): 2477-2480.
Cui JN, Wang JJ. Progress of immunotherapy combined with radiotherapy for advanced non-small cell lung cancer[J]. J Mod Oncol, 2018, 26(15): 2477-2480.
9 Collins AV, Brodie DW, Gilbert RJ, et al. The interaction properties of costimulatory molecules revisited[J]. Immunity, 2002, 17(2): 201-210.
10 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-264.
11 Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma[J]. N Engl J Med, 2013, 369(2): 122-133.
12 Deng WW, Wu L, Sun ZJ. Co-inhibitory immune checkpoints in head and neck squamous cell carcinoma[J]. Oral Dis, 2018, 24(1/2): 120-123.
13 Siu LL, Even C, Mesía R, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial[J]. JAMA Oncol, 2019, 5(2): 195-203.
14 Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma[J]. Cancer Res, 2013, 73(6): 1733-1741.
15 Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol, 2008, 26: 677-704.
16 Bennett F, Luxenberg D, Ling V, et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses[J]. J Immunol, 2003, 170(2): 711-718.
17 Yang B, Liu TJ, Qu Y, et al. Progresses and perspectives of anti-PD-1/PD-L1 antibody therapy in head and neck cancers[J]. Front Oncol, 2018, 8: 563.
18 Ferris RL, Blumenschein G Jr, Fayette J, et al. Ni-volumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016, 375(19): 1856-1867.
19 Ferris RL, Blumenschein G Jr, Fayette J, et al. Ni-volumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression[J]. Oral Oncol, 2018, 81: 45-51.
20 Cohen EEW, Bell RB, Bifulco CB, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)[J]. J Immunother Cancer, 2019, 7(1): 184.
21 Mehra R, Seiwert TY, Gupta S, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012[J]. Br J Cancer, 2018, 119(2): 153-159.
22 Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016, 17(7): 956-965.
23 Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase Ⅱ study[J]. J Clin Oncol, 2017, 35(14): 1542-1549.
24 Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 393(10167): 156-167.
25 Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10212): 1915-1928.
26 Segal NH, Ou SI, Balmanoukian A, et al. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: Results from a phase Ⅰ/Ⅱ expansion cohort[J]. Eur J Cancer, 2019, 109: 154-161.
27 Colevas AD, Bahleda R, Braiteh F, et al. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase Ⅰ trial[J]. Ann Oncol, 2018, 29(11): 2247-2253.
28 Wang YF, Liu ZG, Yuan HF, et al. The reciprocity between radiotherapy and cancer immunotherapy[J]. Clin Cancer Res, 2019, 25(6): 1709-1717.
29 Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class Ⅰ expression, and induces successful antitumor immunotherapy[J]. J Exp Med, 2006, 203(5): 1259-1271.
30 Manukian G, Bar-Ad V, Lu B, et al. Combining radiation and immune checkpoint blockade in the treatment of head and neck squamous cell carcinoma[J]. Front Oncol, 2019, 9: 122.
31 Park SS, Dong HD, Liu X, et al. PD-1 restrains radiotherapy-induced abscopal effect[J]. Cancer Immunol Res, 2015, 3(6): 610-619.
32 Rodriguez-Ruiz ME, Rodriguez I, Garasa S, et al. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming[J]. Cancer Res, 2016, 76(20): 5994-6005.
33 Young KH, Baird JR, Savage T, et al. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy[J]. PLoS One, 2016, 11(6): e0157164.
34 Kiess AP, Wolchok JD, Barker CA, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment[J]. Int J Radiat Oncol Biol Phys, 2015, 92(2): 368-375.
35 Choi JS, Sansoni ER, Lovin BD, et al. Abscopal effect following immunotherapy and combined stereotactic body radiation therapy in recurrent metastatic head and neck squamous cell carcinoma: a report of two cases and literature review[J]. Ann Otol Rhinol Laryngol, 2020, 129(5): 517-522.
36 Wu JS, Jen CW, Chen HH, et al. Stereotactic body radiotherapy and checkpoint inhibitor for locally recurrent unresectable nasopharyngeal carcinoma[J]. BMJ Case Rep, 2021, 14(7): e240806.
37 Elbers JBW, Al-Mamgani A, Tesseslaar MET, et al. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: results from a phase-Ⅰ trial[J]. Radiother Oncol, 2020, 142: 79-84.
38 Biau J, Bourhis J. Combining immunotherapy and radiotherapy in head and neck squamous cell cancers: which perspectives[J]. Curr Opin Oncol, 2020, 32(3): 196-202.
39 Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(20): 1919-1929.
40 Samstein R, Rimner A, Barker CA, et al. Combined immune checkpoint blockade and radiation therapy: timing and dose fractionation associated with greatest survival duration among over 750 treated patients[J]. Int J Radiat Oncol, 2017, 99(2): S129-S130.
41 Vanpouille-Box C, Formenti SC, Demaria S. TREX1 dictates the immune fate of irradiated cancer cells[J]. Oncoimmunology, 2017, 6(9): e1339857.
[1] 刘世一, 陈中, 张素欣. 程序性死亡受体/配体免疫治疗策略在人乳头瘤病毒阳性头颈部鳞状细胞癌中的研究进展[J]. 国际口腔医学杂志, 2024, 51(1): 21-27.
[2] 和子慕, 李风兰. 数字化口腔定位支架在头颈部肿瘤放射治疗中的应用现状[J]. 国际口腔医学杂志, 2024, 51(1): 28-35.
[3] 李奕君, 徐子昂, 李一. 前哨淋巴结在头颈部鳞状细胞癌检测的应用进展[J]. 国际口腔医学杂志, 2023, 50(5): 521-527.
[4] 杨明燕,张帆,赵蕾. 口腔菌群变化影响放射治疗和化学治疗相关性口腔黏膜炎病程的研究进展[J]. 国际口腔医学杂志, 2023, 50(1): 43-51.
[5] 陈小利,张帆,刘程程. 光生物调节在放射治疗后口腔并发症防治中的应用进展[J]. 国际口腔医学杂志, 2022, 49(6): 707-716.
[6] 杨赟琪,林阳阳,侯敏. 手术优先模式颌骨稳定性及影响因素研究进展[J]. 国际口腔医学杂志, 2022, 49(2): 227-232.
[7] 卫彬彬,胡慧维,刘玉娟,孙哲,衣玉丽. 放射治疗前使用氨磷汀对头颈部癌症患者口干症等干预效果的Meta分析和GRADE评价[J]. 国际口腔医学杂志, 2020, 47(5): 547-556.
[8] 陈东,杨征,蒋丽. 放射性口腔干燥症的评估与临床管理的研究进展[J]. 国际口腔医学杂志, 2019, 46(6): 711-717.
[9] 郝福,孙睿. 头颈部鳞状细胞癌第二原发癌的研究进展[J]. 国际口腔医学杂志, 2019, 46(5): 585-592.
[10] 毛璐,鞠侯雨,任国欣. 程序性细胞死亡受体-1与其配体信号通路的调控及其在头颈鳞状细胞癌治疗中的研究进展[J]. 国际口腔医学杂志, 2018, 45(5): 560-565.
[11] 吕丹妮,李容林,杨光伟,李春阳. 放射治疗和化学治疗诱发性口腔黏膜炎的防治[J]. 国际口腔医学杂志, 2015, 42(2): 177-180.
[12] 陈琦 吴芸. 肿痛安治疗癌症放射治疗后颞下颌关节疼痛的疗效评价[J]. 国际口腔医学杂志, 2015, 42(1): 24-27.
[13] 李博勋 刘奕. 外科与正畸联合治疗骨性Ⅰ类双颌前突1例[J]. 国际口腔医学杂志, 2013, 40(4): 462-463.
[14] 王宏伟 齐素青. 下颌后退术对咽腔及其周围解剖结构影响的研究进展[J]. 国际口腔医学杂志, 2013, 40(3): 409-411.
[15] 王亚敏综述 宋光保审校. 放射治疗对口腔种植的影响[J]. 国际口腔医学杂志, 2011, 38(2): 204-206.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 张新春. 桩冠修复与无髓牙的保护[J]. 国际口腔医学杂志, 1999, 26(06): .
[2] 王昆润. 长期单侧鼻呼吸对头颅发育有不利影响[J]. 国际口腔医学杂志, 1999, 26(05): .
[3] 彭国光. 颈淋巴清扫术中颈交感神经干的解剖变异[J]. 国际口腔医学杂志, 1999, 26(05): .
[4] 杨凯. 淋巴化疗的药物运载系统及其应用现状[J]. 国际口腔医学杂志, 1999, 26(05): .
[5] 康非吾. 种植义齿下部结构生物力学研究进展[J]. 国际口腔医学杂志, 1999, 26(05): .
[6] 柴枫. 可摘局部义齿用Co-Cr合金的激光焊接[J]. 国际口腔医学杂志, 1999, 26(04): .
[7] 孟姝,吴亚菲,杨禾. 伴放线放线杆菌产生的细胞致死膨胀毒素及其与牙周病的关系[J]. 国际口腔医学杂志, 2005, 32(06): 458 -460 .
[8] 费晓露,丁一,徐屹. 牙周可疑致病菌对口腔黏膜上皮的粘附和侵入[J]. 国际口腔医学杂志, 2005, 32(06): 452 -454 .
[9] 赵兴福,黄晓晶. 变形链球菌蛋白组学研究进展[J]. 国际口腔医学杂志, 2008, 35(S1): .
[10] 庞莉苹,姚江武. 抛光和上釉对陶瓷表面粗糙度、挠曲强度及磨损性能的影响[J]. 国际口腔医学杂志, 2008, 35(S1): .